Global Oncology Drugs Market Briefing 2018 provides strategists, marketers and senior management with the critical information they need to assess the global oncology drugs sector.
Oncology deals with diagnosis, prevention and treatment of cancer diseases. Anti-cancer or anti-neoplastic agents are the drugs that prevent or inhibit or halt the proliferation and maturation of neoplasms, an abnormal growth of tissues commonly referred as tumors. These drugs prevent the growth of malignant tumors by affecting the process of cell division or by damaging the DNA and initiate apoptosis or by preventing the development and spread of neoplastic cells. Several types of cancers that can be treated by oncology drugs are blood cancer, lung cancer, endocrine cancer, bone cancer, gastric cancer, colorectal cancer, skin cancer, breast cancer, pancreatic cancer, prostate cancers, ovarian cancer, ocular cancer and others.
North America was the largest region in the oncology drugs market in 2017, accounting for around 31% market share. North America has the highest GDP that allows it to afford the latest and patented oncology medicines which are comparatively higher or difficult to access when compared with other regions. Asia Pacific was the second largest region accounting for around 25% market share. Middle East was the seventh largest region accounting for around 4% market share.
Collaboration Driving Innovation - Companies in the oncology drug market are increasing their product innovation through strategic collaborations. to sustain in the increasingly competitive oncology drug market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as academic and research institutions in this market by striking partnering, in or out licensing deals, this trend may have increased in recent years.
For instance, in January 2016, AstraZeneca and Moderna Therapeutics entered into a collaboration to discover, co-develop and co-commercialize immuno-oncology mRNA therapeutics for the treatment of cardiovascular, metabolic and renal diseases as well as selected targets in oncology. Servier and Novartis have also extended their collaboration to co-develop and commercialize anti-Mcl-1 drug candidates for cancer treatment.
- Markets Covered: Blood Cancer, Breast Cancer, Cervical Cancer, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Kidney Cancer, Gastric Cancer, Brain Tumor, Pancreatic Cancer, Skin Cancer, Ovarian Cancer, Bladder Cancer, Thyroid Cancer, Others.
- Time Series: Five years historic and forecast.
- Data: Market value in $ billions.
- Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Gilead Sciences Inc.
- Bayer AG
- Takeda Pharmaceuticals
- Johnson & Johnson
- Pfizer Inc.
- Boehringer Ingelheim GmbH
- Eli Lilly
- Otsuka Pharmaceutical Co. Ltd
For more information about this report visit https://www.researchandmarkets.com/research/6wn6kx/global_oncology?w=4